The Life Sciences team advised Anagram Therapeutics (Anagram) on a $250 million investment from Blackstone Life Sciences (BXLS). The investment will help fund the further development, approval, and launch of Anagram’s ANG003, a novel orally delivered recombinant enzyme replacement therapy that has demonstrated positive clinical data in people with exocrine pancreatic insufficiency (EPI) due to CF. This community currently faces a highly disruptive pill burden, taking up to 40 pills daily. Additionally, ANG003 has the potential to be the first non-porcine extract product.
Anagram Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of serious diseases caused by malabsorption syndromes and nutrient metabolism disorders, a group of conditions caused by enzyme deficiencies or genetic disorders that prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins, or other key nutrients. The company is leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can have a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. ANG003, Anagram’s lead product for the treatment of malabsorption and exocrine pancreatic insufficiency, is a new class of broad-spectrum digestive enzyme replacement therapy in clinical trials in people with exocrine pancreatic insufficiency due to cystic fibrosis. Anagram is a privately held company headquartered in Natick, MA.
The Goodwin team was led by Michael Bison, Michael Parisse, Bartek Sudol, Alesha Neumann, Yasin Akbari, Shannyn Henke, Nancy Urizar, Evan De Ycaza, Duncan Greenhalgh, Megan Gustafson, Simone Waterbury, Kevin Walsh, Arman Oruc, Reid Bagwell, and Dan Karelitz.
For more information on the deal, please read the press release.